
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ozanimod
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Zydus Lifesciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Zydus and Synthon Entered into Exclusive Licensing and Supply Agreement for Ozanimod
Details : Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product (generic version of Zeposia), and thereafter, for the manufacture and supply of the product.
Product Name : Zeposia
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 04, 2025
Lead Product(s) : Ozanimod
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Zydus Lifesciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Zydus Lifesciences
Deal Size : Undisclosed
Deal Type : Agreement
Zydus Lifesciences in Pact with Synthon for Specialty Oncology Product in US
Details : Zydus to handle NDA submission and commercialisation in the US and Synthon to lead development and manufacturing for oncology product.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 12, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Zydus Lifesciences
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of GTR in Comparison to Copaxone®
Details : Glatiramer Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2011
Lead Product(s) : Glatiramer Acetate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
